Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 7/20 | 0.50 |
| ▸ | DRD5 | P21918 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092656 | 0.90 | MEN1 (0.57) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL2632890 | 0.86 | NOTUM (0.52) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL12718802 | 0.86 | HRH3 (0.51) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL8067706 | 0.85 | DRD1 (0.50) | DRD1DRD5DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7840936 | 0.81 | DRD1 (0.47) | DRD1DRD5DRD2DRD3DRD4 | |
| Ammonia Solution, Strong SCHEMBL905865 | 0.80 | ALDH1A1 (0.47) | DRD2DRD4MEN1ALDH1A1KMT2A | |
| SCHEMBL23489361 | 0.79 | MAPT (0.50) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL10490519 | 0.79 | HRH3 (0.52) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL30739441 | 0.79 | KDM4E (0.49) | DRD1DRD5DRD2DRD3DRD4 | |
| Ammonia Solution, Strong SCHEMBL905757 | 0.78 | HTR2A (0.60) | MEN1ALDH1A1KMT2AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | claimed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | DRD1 505/4885DRD5 238/4885DRD2 208/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | DRD1 505/4885DRD5 238/4885DRD2 208/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | DRD1 505/4885DRD5 238/4885DRD2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.